In the KLN205 lung squamous cell carcinoma syngeneic model, the combination of niraparib and anti-PD-1 demonstrated enhanced antitumor activity and resulted in 52% TGI, compared to the results of niraparib monotherapy, with 36% TGI, and anti-PD-1 monotherapy, with 30% TGI (Fig. 5D), suggesting a combination benefit in this model. Here, PDCD1 is linked to squamous cell lung carcinoma.